...
首页> 外文期刊>Journal of Medicinal Chemistry >Bifunctional Naphtho[2,3-d][1,2,3]triazole-4,9-dione Compounds Exhibit Antitumor Effects In Vitro and In Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production
【24h】

Bifunctional Naphtho[2,3-d][1,2,3]triazole-4,9-dione Compounds Exhibit Antitumor Effects In Vitro and In Vivo by Inhibiting Dihydroorotate Dehydrogenase and Inducing Reactive Oxygen Species Production

机译:双官能萘[2,3-D] [1,2,3]三唑-4,9-二酮化合物通过抑制二氢脱氢酶和诱导反应性氧物种生产,在体外和体内表现出抗肿瘤作用

获取原文
获取原文并翻译 | 示例

摘要

Human dihydroorotate dehydrogenase (hDHODH) is an attractive target for cancer therapy. Based on its crystal structure, we designed and synthesized a focused compound library containing the structural moiety of 1,4-benzoquinone, which possesses reactive oxygen species (ROS) induction capacity. Compound 3s with a naphtho[2,3-d][1,2,3]-triazole-4,9-dione scaffold exhibited inhibitory activity against hDHODH. Further optimization led to compounds 11k and 11l, which inhibited hDHODH activity with IC50 values of 9 and 4.5 nM, respectively. Protein-ligand cocrystal structures clearly depicted hydrogen bond and hydrophobic interactions of 11k and 11l with hDHODH. Compounds 11k and 11l significantly inhibited leukemia cell and solid tumor cell proliferation and induced ROS production, mitochondrial dysfunction, apoptosis, and cell cycle arrest. Nanocrystallization of compound 11l displayed significant in vivo antitumor effects in the Raji xenograft model. Overall, this study provides a novel bifunctional compound 11l with hDHODH inhibition and ROS induction efficacy, which represents a promising anticancer lead worthy of further exploration.
机译:人的二氢脱氢酶(HDhodh)是癌症治疗的有吸引力的靶标。基于其晶体结构,我们设计和合成了含有1,4-苯醌的结构部分的聚焦复合文库,其具有反应性氧(ROS)诱导能力。用萘[2,3-D]的化合物3S [2,3-D] [1,2,3] - 4,9-二酮支架表现出对Hdhodh的抑制活性。进一步优化导致化合物11K和11L,其抑制了IC 50值9和4.5nm的HDHodh活性。蛋白质 - 配体COCRYSTAL结构清楚地描绘了11K和11L的氢键和疏水相互作用,HDHodh。化合物11K和11L显着抑制白血病细胞和实体肿瘤细胞增殖,诱导ROS生产,线粒体功能障碍,细胞凋亡和细胞周期停滞。在Raji异种移植模型中的体内抗肿瘤效应中显示出大型化合物11L的纳米晶。总体而言,该研究提供了一种新型双官能化合物11L,具有HDHodh抑制和ROS诱导疗效,这代表了一个有价值的抗癌率,值得进一步探索。

著录项

  • 来源
    《Journal of Medicinal Chemistry 》 |2020年第14期| 共20页
  • 作者单位

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp Dept Pharm Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp State Key Lab Biotherapy West China Med Sch Chengdu 610041 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学 ;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号